Log in

NASDAQ:IMABPhoenix Tree News Headlines

$24.93
+0.58 (+2.38 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.03
Now: $24.93
$25.18
50-Day Range
$13.10
MA: $16.95
$26.16
52-Week Range
$9.30
Now: $24.93
$32.89
Volume15,975 shs
Average Volume73,123 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Phoenix Tree (NASDAQ IMAB) News Headlines

Source:
DateHeadline
Phoenix Tree (IMAB) & Its Rivals Critical ContrastPhoenix Tree (IMAB) & Its Rivals Critical Contrast
www.americanbankingnews.com - May 29 at 12:37 PM
I-Mab Announces Upcoming Participation at June ConferencesI-Mab Announces Upcoming Participation at June Conferences
finance.yahoo.com - May 29 at 10:12 AM
I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with -Cytokine Release SyndromeI-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with -Cytokine Release Syndrome
finance.yahoo.com - May 27 at 4:56 PM
Phoenix Tree Holdings Limited (NASDAQ:IMAB) Expected to Announce Earnings of -$0.51 Per SharePhoenix Tree Holdings Limited (NASDAQ:IMAB) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - May 27 at 2:13 PM
Reviewing Phoenix Tree (IMAB) and The CompetitionReviewing Phoenix Tree (IMAB) and The Competition
www.americanbankingnews.com - May 26 at 5:09 PM
PHOENIX LOSS ALERT, ROSEN, A TOP RANKED INVESTOR FIRM, Reminds Phoenix Tree Holdings Limited Investors of Important Deadline in Securities Class Action – DNKPHOENIX LOSS ALERT, ROSEN, A TOP RANKED INVESTOR FIRM, Reminds Phoenix Tree Holdings Limited Investors of Important Deadline in Securities Class Action – DNK
www.businesswire.com - May 22 at 10:50 AM
Zacks: Phoenix Tree Holdings Limited (NASDAQ:IMAB) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Phoenix Tree Holdings Limited (NASDAQ:IMAB) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 21 at 10:06 AM
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma MultiformeI-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme
finance.yahoo.com - May 21 at 9:32 AM
I-Mab Expands Global Presence with New Hong Kong OfficeI-Mab Expands Global Presence with New Hong Kong Office
finance.yahoo.com - May 20 at 4:31 AM
Critical Survey: Phoenix Tree (IMAB) & Its RivalsCritical Survey: Phoenix Tree (IMAB) & Its Rivals
www.americanbankingnews.com - May 19 at 8:57 AM
Danke Releases China Residential Rental Industrys First Company Standard for Indoor Air QualityDanke Releases China Residential Rental Industry's First Company Standard for Indoor Air Quality
www.prnewswire.com - May 14 at 5:37 AM
First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid TumorsFirst Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors
finance.yahoo.com - May 13 at 12:51 PM
I-Mab Filed 2019 Annual Report on Form 20-FI-Mab Filed 2019 Annual Report on Form 20-F
finance.yahoo.com - April 29 at 11:10 AM
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland ChinaI-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
finance.yahoo.com - April 27 at 5:16 PM
I-Mab Announces Upcoming Participation at May ConferencesI-Mab Announces Upcoming Participation at May Conferences
finance.yahoo.com - April 24 at 4:22 PM
Phoenix Tree (DNK) Alert: Johnson Fistel Investigates China Based Phoenix Tree Holdings; Investors Suffering Losses Encouraged to Contact FirmPhoenix Tree (DNK) Alert: Johnson Fistel Investigates China Based Phoenix Tree Holdings; Investors Suffering Losses Encouraged to Contact Firm
www.prnewswire.com - April 16 at 8:48 PM
Danke Obtains WELL Silver Certification for Co-living Project in BeijingDanke Obtains WELL Silver Certification for Co-living Project in Beijing
www.prnewswire.com - April 13 at 12:15 AM
I-Mab Announces Upcoming Participation at April ConferencesI-Mab Announces Upcoming Participation at April Conferences
finance.yahoo.com - April 6 at 3:54 PM
I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
finance.yahoo.com - April 3 at 3:48 PM
I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in ChinaI-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China
finance.yahoo.com - April 2 at 4:31 PM
I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate UpdateI-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update
finance.yahoo.com - March 31 at 11:09 AM
I-Mab - ADR to Host Earnings CallI-Mab - ADR to Host Earnings Call
finance.yahoo.com - March 31 at 6:08 AM
I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-OncologyI-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology
finance.yahoo.com - March 30 at 8:07 PM
I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South KoreaI-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
finance.yahoo.com - March 30 at 8:07 PM
I-Mab Expands Global Out-Licensing and Business Development EffortsI-Mab Expands Global Out-Licensing and Business Development Efforts
finance.yahoo.com - March 27 at 9:25 AM
I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)
finance.yahoo.com - March 13 at 9:31 AM
I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020
finance.yahoo.com - March 11 at 2:49 PM
I-Mab Announces Upcoming Participation at March ConferencesI-Mab Announces Upcoming Participation at March Conferences
finance.yahoo.com - February 25 at 12:00 PM
I-MAB Announces Pricing of U.S. Initial Public OfferingI-MAB Announces Pricing of U.S. Initial Public Offering
finance.yahoo.com - February 12 at 5:37 PM
Buyout Firm CBC Eyes More Listings After I-Mab Debut in U.S.Buyout Firm CBC Eyes More Listings After I-Mab Debut in U.S.
finance.yahoo.com - February 12 at 5:37 PM
I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public OfferingI-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
finance.yahoo.com - February 12 at 5:37 PM
This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.